-
Je něco špatně v tomto záznamu ?
Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF): a phase 2, pharmacokinetic, randomised, placebo-controlled trial
JR. Teerlink, GM. Felker, JJ. McMurray, SD. Solomon, KF. Adams, JG. Cleland, JA. Ezekowitz, A. Goudev, P. Macdonald, M. Metra, V. Mitrovic, P. Ponikowski, P. Serpytis, J. Spinar, J. Tomcsányi, HJ. Vandekerckhove, AA. Voors, ML. Monsalvo, J....
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu klinické zkoušky, fáze II, časopisecké články, multicentrická studie, randomizované kontrolované studie, práce podpořená grantem
NLK
ProQuest Central
od 1992-01-04 do Před 3 měsíci
Nursing & Allied Health Database (ProQuest)
od 1992-01-04 do Před 3 měsíci
Health & Medicine (ProQuest)
od 1992-01-04 do Před 3 měsíci
Family Health Database (ProQuest)
od 1992-01-04 do Před 3 měsíci
Psychology Database (ProQuest)
od 1992-01-04 do Před 3 měsíci
Health Management Database (ProQuest)
od 1992-01-04 do Před 3 měsíci
Public Health Database (ProQuest)
od 1992-01-04 do Před 3 měsíci
- MeSH
- aplikace orální * MeSH
- funkce levé komory srdeční účinky léků MeSH
- lidé MeSH
- močovina aplikace a dávkování analogy a deriváty farmakokinetika MeSH
- natriuretický peptid typu B MeSH
- peptidové fragmenty MeSH
- remodelace komor účinky léků MeSH
- srdeční myosiny metabolismus farmakokinetika MeSH
- srdeční selhání farmakoterapie patofyziologie MeSH
- systola MeSH
- tepový objem účinky léků MeSH
- vztah mezi dávkou a účinkem léčiva MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- klinické zkoušky, fáze II MeSH
- multicentrická studie MeSH
- práce podpořená grantem MeSH
- randomizované kontrolované studie MeSH
BACKGROUND: Impaired contractility is a feature of heart failure with reduced ejection fraction. We assessed the pharmacokinetics and effects on cardiac function and structure of the cardiac myosin activator, omecamtiv mecarbil. METHODS: In this randomised, double-blind study, done at 87 sites in 13 countries, we recruited patients with stable, symptomatic chronic heart failure and left ventricular ejection fraction 40% or lower. Patients were randomly assigned equally, via an interactive web response system, to receive 25 mg oral omecamtiv mecarbil twice daily (fixed-dose group), 25 mg twice daily titrated to 50 mg twice daily guided by pharmacokinetics (pharmacokinetic-titration group), or placebo for 20 weeks. We assessed the maximum concentration of omecamtiv mecarbil in plasma (primary endpoint) and changes in cardiac function and ventricular diameters. This trial is registered with ClinicalTrials.gov, number NCT01786512. FINDINGS: From March 17, 2014, to March 5, 2015, we enrolled 150 patients in the fixed-dose omecamtiv mecarbil group and 149 in the pharmacokinetic-titration and placebo groups. Mean maximum concentration of omecamtiv mecarbil at 12 weeks was 200 (SD 71) ng/mL in the fixed-dose group and 318 (129) ng/mL in the pharmacokinetic-titration group. For the pharmacokinetic-titration group versus placebo group at 20 weeks, least square mean differences were as follows: systolic ejection time 25 ms (95% CI 18-32, p<0·0001), stroke volume 3·6 mL (0·5-6·7, p=0·0217), left ventricular end-systolic diameter -1·8 mm (-2·9 to -0·6, p=0·0027), left ventricular end-diastolic diameter -1·3 mm, (-2·3 to 0·3, p=0·0128), heart rate -3·0 beats per min (-5·1 to -0·8, p=0·0070), and N-terminal pro B-type natriuretic peptide concentration in plasma -970 pg/mL (-1672 to -268, p=0·0069). The frequency of adverse clinical events did not differ between groups. INTERPRETATION: Omecamtiv mecarbil dosing guided by pharmacokinetics achieved plasma concentrations associated with improved cardiac function and decreased ventricular diameter. FUNDING: Amgen.
British Heart Foundation Cardiovascular Research Centre University of Glasgow Glasgow UK
Cardiology Department St John of God Hospital Budapest Hungary
Cytokinetics South San Francisco CA USA
Department of Cardiology AZ St Lucas Ghent Belgium
Department of Medicine University of Alberta Edmonton AB Canada
Division of Cardiology Duke University School of Medicine Durham NC USA
Division of Cardiology University of Brescia Brescia Italy
Division of Cardiology University of North Carolina at Chapel Hill Chapel Hill NC USA
Johann Wolfgang Goethe University Main Germany
Kerckhoff Klinik Forschungsgesellschaft Frankfurt Germany
National Heart and Lung Institute Royal Brompton and Harefield Hospitals Imperial College London UK
Robertson Centre for Biostatistics and Clinical Trials University of Glasgow Glasgow UK
School of Medicine University of California San Francisco San Francisco CA USA
Section of Cardiology San Francisco Veterans Affairs Medical Center San Francisco CA USA
University Hospital Brno and Medical Faculty of Masaryk University Brno Czech Republic
University of Groningen University Medical Centre Groningen Groningen Netherlands
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc17031246
- 003
- CZ-PrNML
- 005
- 20191213094810.0
- 007
- ta
- 008
- 171025s2016 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/S0140-6736(16)32049-9 $2 doi
- 035 __
- $a (PubMed)27914656
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Teerlink, John R $u School of Medicine, University of California San Francisco, San Francisco, CA, USA; Section of Cardiology, San Francisco Veterans Affairs Medical Center, San Francisco, CA, USA. Electronic address: john.teerlink@ucsf.edu.
- 245 10
- $a Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF): a phase 2, pharmacokinetic, randomised, placebo-controlled trial / $c JR. Teerlink, GM. Felker, JJ. McMurray, SD. Solomon, KF. Adams, JG. Cleland, JA. Ezekowitz, A. Goudev, P. Macdonald, M. Metra, V. Mitrovic, P. Ponikowski, P. Serpytis, J. Spinar, J. Tomcsányi, HJ. Vandekerckhove, AA. Voors, ML. Monsalvo, J. Johnston, FI. Malik, N. Honarpour, . ,
- 520 9_
- $a BACKGROUND: Impaired contractility is a feature of heart failure with reduced ejection fraction. We assessed the pharmacokinetics and effects on cardiac function and structure of the cardiac myosin activator, omecamtiv mecarbil. METHODS: In this randomised, double-blind study, done at 87 sites in 13 countries, we recruited patients with stable, symptomatic chronic heart failure and left ventricular ejection fraction 40% or lower. Patients were randomly assigned equally, via an interactive web response system, to receive 25 mg oral omecamtiv mecarbil twice daily (fixed-dose group), 25 mg twice daily titrated to 50 mg twice daily guided by pharmacokinetics (pharmacokinetic-titration group), or placebo for 20 weeks. We assessed the maximum concentration of omecamtiv mecarbil in plasma (primary endpoint) and changes in cardiac function and ventricular diameters. This trial is registered with ClinicalTrials.gov, number NCT01786512. FINDINGS: From March 17, 2014, to March 5, 2015, we enrolled 150 patients in the fixed-dose omecamtiv mecarbil group and 149 in the pharmacokinetic-titration and placebo groups. Mean maximum concentration of omecamtiv mecarbil at 12 weeks was 200 (SD 71) ng/mL in the fixed-dose group and 318 (129) ng/mL in the pharmacokinetic-titration group. For the pharmacokinetic-titration group versus placebo group at 20 weeks, least square mean differences were as follows: systolic ejection time 25 ms (95% CI 18-32, p<0·0001), stroke volume 3·6 mL (0·5-6·7, p=0·0217), left ventricular end-systolic diameter -1·8 mm (-2·9 to -0·6, p=0·0027), left ventricular end-diastolic diameter -1·3 mm, (-2·3 to 0·3, p=0·0128), heart rate -3·0 beats per min (-5·1 to -0·8, p=0·0070), and N-terminal pro B-type natriuretic peptide concentration in plasma -970 pg/mL (-1672 to -268, p=0·0069). The frequency of adverse clinical events did not differ between groups. INTERPRETATION: Omecamtiv mecarbil dosing guided by pharmacokinetics achieved plasma concentrations associated with improved cardiac function and decreased ventricular diameter. FUNDING: Amgen.
- 650 12
- $a aplikace orální $7 D000284
- 650 _2
- $a srdeční myosiny $x metabolismus $x farmakokinetika $7 D024722
- 650 _2
- $a vztah mezi dávkou a účinkem léčiva $7 D004305
- 650 _2
- $a srdeční selhání $x farmakoterapie $x patofyziologie $7 D006333
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a natriuretický peptid typu B $7 D020097
- 650 _2
- $a peptidové fragmenty $7 D010446
- 650 _2
- $a tepový objem $x účinky léků $7 D013318
- 650 _2
- $a systola $7 D013599
- 650 _2
- $a močovina $x aplikace a dávkování $x analogy a deriváty $x farmakokinetika $7 D014508
- 650 _2
- $a funkce levé komory srdeční $x účinky léků $7 D016277
- 650 _2
- $a remodelace komor $x účinky léků $7 D020257
- 655 _2
- $a klinické zkoušky, fáze II $7 D017427
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a multicentrická studie $7 D016448
- 655 _2
- $a randomizované kontrolované studie $7 D016449
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Felker, G Michael $u Division of Cardiology, Duke University School of Medicine, Durham, NC, USA.
- 700 1_
- $a McMurray, John J V $u British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.
- 700 1_
- $a Solomon, Scott D. $7 xx0243096 $u Division of Cardiovascular Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
- 700 1_
- $a Adams, Kirkwood F $u Division of Cardiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. $7 gn_A_00001580
- 700 1_
- $a Cleland, John G F $u National Heart and Lung Institute, Royal Brompton and Harefield Hospitals, Imperial College, London, UK; Robertson Centre for Biostatistics and Clinical Trials, University of Glasgow, Glasgow, UK.
- 700 1_
- $a Ezekowitz, Justin A $u Department of Medicine, University of Alberta, Edmonton, AB, Canada.
- 700 1_
- $a Goudev, Assen $u Department of Cardiology, Queen Giovanna University Hospital and Medical University-Sofia, Sofia, Bulgaria.
- 700 1_
- $a Macdonald, Peter $u Heart Transplant Unit, St Vincent's Hospital and Transplantation Research Laboratory, Victor Chang Cardiac Research Institute and University of New South Wales, Sydney, NSW, Australia.
- 700 1_
- $a Metra, Marco $u Division of Cardiology, University of Brescia, Brescia, Italy.
- 700 1_
- $a Mitrovic, Veselin $u Kerckhoff-Klinik Forschungsgesellschaft, Frankfurt, Germany; Johann-Wolfgang Goethe University, Main, Germany.
- 700 1_
- $a Ponikowski, Piotr $u Department of Heart Diseases, Medical University and Centre for Heart Diseases, Military Hospital, Wrocław, Poland.
- 700 1_
- $a Serpytis, Pranas $u Emergency Centre, Vilnius University Hospital Santariskiu Klinikos and Vilnius University, Vilnius, Lithuania.
- 700 1_
- $a Spinar, Jindrich $u University Hospital Brno and Medical Faculty of Masaryk University, Brno, Czech Republic.
- 700 1_
- $a Tomcsányi, János $u Cardiology Department, St John of God Hospital, Budapest, Hungary.
- 700 1_
- $a Vandekerckhove, Hans J $u Department of Cardiology, AZ-St-Lucas, Ghent, Belgium.
- 700 1_
- $a Voors, Adriaan A $u University of Groningen, University Medical Centre Groningen, Groningen, Netherlands.
- 700 1_
- $a Monsalvo, Maria Laura $u Amgen, Thousand Oaks, CA, USA.
- 700 1_
- $a Johnston, James $u Amgen, Thousand Oaks, CA, USA.
- 700 1_
- $a Malik, Fady I $u Cytokinetics, South San Francisco, CA, USA.
- 700 1_
- $a Honarpour, Narimon $u Amgen, Thousand Oaks, CA, USA.
- 700 1_
- $a ,
- 773 0_
- $w MED00010161 $t Lancet (London, England) $x 1474-547X $g Roč. 388, č. 10062 (2016), s. 2895-2903
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/27914656 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20171025 $b ABA008
- 991 __
- $a 20191213095111 $b ABA008
- 999 __
- $a ok $b bmc $g 1254839 $s 992273
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2016 $b 388 $c 10062 $d 2895-2903 $e 20161201 $i 1474-547X $m Lancet $n Lancet $x MED00010161
- LZP __
- $a Pubmed-20171025
